Research
Hormonal
Specific probiotic strains (e.g., Bifidobacterium pseudocatenulatum CECT 7765) can reduce stress-induced corticosterone levels and improve depressive-like behavior in obese animal models by modulating the gut microbiota.
This specific probiotic strain showed promise in reducing stress hormones in obese mice. While human results are not guaranteed, it suggests that targeted probiotic supplementation might be worth exploring for stress and mood management in obesity, alongside diet changes.
LimitedSupportsLOW confidence
Agusti et al. (2017) demonstrated that basal corticosterone levels were significantly increased in mice with HFD-induced obesity... Administration of B. pseudocatenulatum CECT 7765 reduced corticosterone levels in HDF-fed mice, indicating that an intervention primarily targeting the gut was able to reverse the anxiogenic obese profile.
Why this rating
Based on a single cited animal study (Agusti et al., 2017) within a review; no human clinical trial data provided for this specific strain.
Source
Interplay Between the Gut-Brain Axis, Obesity and Cognitive Function
Ana Agustí et al. · Frontiers in Neuroscience · 2018
DOI 10.3389/fnins.2018.00155
narrative_reviewCited 295×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity-associated gut dysbiosis contributes to cognitive and mood deficits through the activation of the HPA-axis, leading to glucocorticoid overproduction, and the promotion of a pro-inflammatory milieu (endotoxemia/leaky gut) that causes neuro-inflammation.Moderate
- Western dietary patterns (high fat/sugar) cause gut dysbiosis and 'leaky gut' (increased permeability), allowing bacterial endotoxins (LPS) to enter circulation, triggering systemic and neuro-inflammation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →